Order Article Reprints

Turinetto M, Ricotti A, Marchetti C, Pisano C, Zamagni C, Cassani C, Malaguti P, Baldoni A, Scollo P, Scandurra G, et al. MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study. Cancers. 2024; 16(1):41. https://doi.org/10.3390/cancers16010041

Turinetto, Margherita, Andrea Ricotti, Claudia Marchetti, Carmela Pisano, Claudio Zamagni, Chiara Cassani, Paola Malaguti, Alessandra Baldoni, Paolo Scollo, Giuseppa Scandurra, and et al. 2024. "MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study" Cancers 16, no. 1: 41. https://doi.org/10.3390/cancers16010041

Turinetto, M., Ricotti, A., Marchetti, C., Pisano, C., Zamagni, C., Cassani, C., Malaguti, P., Baldoni, A., Scollo, P., Scandurra, G., Parisi, A., Artioli, G., Palaia, I., Vertechy, L., Bergamini, A., Picardo, E., Tuninetti, V., Scotto, G., Scambia, G., ... Valabrega, G. (2024). MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study. Cancers, 16(1), 41. https://doi.org/10.3390/cancers16010041